Selection-based design of in silico dengue epitope ensemble vaccines

David Murphy; Pedro Reche; Darren R Flower

doi:10.1111/cbdd.13357

Selection-based design of in silico dengue epitope ensemble vaccines

David Murphy
, Pedro Reche
, Darren R Flower

Aston University
Immunomedicine Group, Facultad de Medicina, Departamento de Microbiologia I; Universidad Complutense de Madrid; Madrid Spain

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

64 Downloads (Pure)

Abstract

Dengue virus affects approximately 130 countries. 25% of infections result in febrile, self‐limiting illness; heterotypic infection results in potentially fatal Dengue Haemorrhagic Fever or Dengue Shock Syndrome. Only one vaccine is currently available. Its efficacy is very variable. Thus, to target Dengue, we used an innovative immunoinformatic protocol to design a putative epitope ensemble vaccine by selecting an optimal set of highly‐conserved epitopes with experimentally‐verified immunogenicity. From 1597 CD4+ and MHC II epitopes, 6 MHC Class I epitopes (RAVHADMGYW, GPWHLGKLEM, GLYGNGVVTK, NMIIMDEAHF, KTWAYHGSY, WAYHGSYEV) and 9 MHC Class II epitopes (LAKAIFKLTYQNKVV, GKIVGLYGNGVVTTS, AAIFMTATPPGSVEA, AAIFMTATPPGTADA, GKTVWFVPSIKAGND, KFWNTTIAVSMANIF, RAIWYMWLGARYLEF, VGTYGLNTFTNMEVQ, WTLMYFHRRDLRLAA) were selected; this candidate vaccine achieved a world population coverage of 92.49%.

Original language	English
Pages (from-to)	21-28
Number of pages	8
Journal	Chemical Biology and Drug Design
Volume	93
Issue number	1
Early online date	25 Nov 2018
DOIs	https://doi.org/10.1111/cbdd.13357
Publication status	Published - Jan 2019

Bibliographical note

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.© 2018 The Authors.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/cbdd.13357Licence: CC BY 3.0

Selection‐based design of in silico dengue epitope ensemble vaccines
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.© 2018 The Authors.
Final published version, 526 KBLicence: CC BY 3.0

Cite this

@article{682a04df00304fa8a927ebe6c3d0edae,

title = "Selection-based design of in silico dengue epitope ensemble vaccines",

abstract = "Dengue virus affects approximately 130 countries. 25\% of infections result in febrile, self‐limiting illness; heterotypic infection results in potentially fatal Dengue Haemorrhagic Fever or Dengue Shock Syndrome. Only one vaccine is currently available. Its efficacy is very variable. Thus, to target Dengue, we used an innovative immunoinformatic protocol to design a putative epitope ensemble vaccine by selecting an optimal set of highly‐conserved epitopes with experimentally‐verified immunogenicity. From 1597 CD4+ and MHC II epitopes, 6 MHC Class I epitopes (RAVHADMGYW, GPWHLGKLEM, GLYGNGVVTK, NMIIMDEAHF, KTWAYHGSY, WAYHGSYEV) and 9 MHC Class II epitopes (LAKAIFKLTYQNKVV, GKIVGLYGNGVVTTS, AAIFMTATPPGSVEA, AAIFMTATPPGTADA, GKTVWFVPSIKAGND, KFWNTTIAVSMANIF, RAIWYMWLGARYLEF, VGTYGLNTFTNMEVQ, WTLMYFHRRDLRLAA) were selected; this candidate vaccine achieved a world population coverage of 92.49\%.",

author = "David Murphy and Pedro Reche and Flower, \{Darren R\}",

note = "This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.{\textcopyright} 2018 The Authors. ",

year = "2019",

month = jan,

doi = "10.1111/cbdd.13357",

language = "English",

volume = "93",

pages = "21--28",

journal = "Chemical Biology and Drug Design",

issn = "1747-0277",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - Selection-based design of in silico dengue epitope ensemble vaccines

AU - Murphy, David

AU - Reche, Pedro

AU - Flower, Darren R

N1 - This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.© 2018 The Authors.

PY - 2019/1

Y1 - 2019/1

N2 - Dengue virus affects approximately 130 countries. 25% of infections result in febrile, self‐limiting illness; heterotypic infection results in potentially fatal Dengue Haemorrhagic Fever or Dengue Shock Syndrome. Only one vaccine is currently available. Its efficacy is very variable. Thus, to target Dengue, we used an innovative immunoinformatic protocol to design a putative epitope ensemble vaccine by selecting an optimal set of highly‐conserved epitopes with experimentally‐verified immunogenicity. From 1597 CD4+ and MHC II epitopes, 6 MHC Class I epitopes (RAVHADMGYW, GPWHLGKLEM, GLYGNGVVTK, NMIIMDEAHF, KTWAYHGSY, WAYHGSYEV) and 9 MHC Class II epitopes (LAKAIFKLTYQNKVV, GKIVGLYGNGVVTTS, AAIFMTATPPGSVEA, AAIFMTATPPGTADA, GKTVWFVPSIKAGND, KFWNTTIAVSMANIF, RAIWYMWLGARYLEF, VGTYGLNTFTNMEVQ, WTLMYFHRRDLRLAA) were selected; this candidate vaccine achieved a world population coverage of 92.49%.

AB - Dengue virus affects approximately 130 countries. 25% of infections result in febrile, self‐limiting illness; heterotypic infection results in potentially fatal Dengue Haemorrhagic Fever or Dengue Shock Syndrome. Only one vaccine is currently available. Its efficacy is very variable. Thus, to target Dengue, we used an innovative immunoinformatic protocol to design a putative epitope ensemble vaccine by selecting an optimal set of highly‐conserved epitopes with experimentally‐verified immunogenicity. From 1597 CD4+ and MHC II epitopes, 6 MHC Class I epitopes (RAVHADMGYW, GPWHLGKLEM, GLYGNGVVTK, NMIIMDEAHF, KTWAYHGSY, WAYHGSYEV) and 9 MHC Class II epitopes (LAKAIFKLTYQNKVV, GKIVGLYGNGVVTTS, AAIFMTATPPGSVEA, AAIFMTATPPGTADA, GKTVWFVPSIKAGND, KFWNTTIAVSMANIF, RAIWYMWLGARYLEF, VGTYGLNTFTNMEVQ, WTLMYFHRRDLRLAA) were selected; this candidate vaccine achieved a world population coverage of 92.49%.

UR - https://onlinelibrary.wiley.com/doi/abs/10.1111/cbdd.13357

U2 - 10.1111/cbdd.13357

DO - 10.1111/cbdd.13357

M3 - Article

SN - 1747-0277

VL - 93

SP - 21

EP - 28

JO - Chemical Biology and Drug Design

JF - Chemical Biology and Drug Design

IS - 1

ER -

Selection-based design of in silico dengue epitope ensemble vaccines

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this